logo
Excellence in Oncology
Ingredients for Society

Our primary specialization lies in developing and manufacturing highly potent
Active Pharmaceutical Ingredients (APIs), primarily used in cancer therapies.

Company

Our mission is to advance global health

The Synbias-Gemini Group operates under the umbrella of Synbias Pharma AG, headquartered in Schaffhausen, Switzerland, which 100% shareholder of Gemini PharmChem Mannheim GmbH, our production facilities, a highly esteemed manufacturing and R&D site located in Mannheim, Germany.

Read more
30-50%

of the world market of particular API 21 countries

21
countries

Our APIs are shipped to customers in 21 countries

15
inspections

Successfully passed through FDA, Anvisa, cGMP and others

Inspections

Compliance You Can Trust

At Synbias-Gemini Group, we have a distinguished track record with global regulatory agencies, demonstrating our unwavering commitment to compliance and quality. Our collaborative approach ensures robust support to our customers through all phases of regulatory submission, ensuring that every product we manufacture meets the highest standards.

Inspection History (2012-2024)

  • Germany Regierungspräsidium Tübingen (German authority): 8 inspections
  • US FDA: 1 inspection
Read More
Anthracyclines
Nucleosides

Products

Our technology allows us to be competitive

At Synbias-Gemini Group, our research and development pipeline is dedicated to advancing cancer treatments through the development of innovative and highly effective active pharmaceutical ingredients (APIs). These efforts are backed by our state-of-the-art facilities and a team of highly skilled scientists committed to excellence.

Read More

Contacts

Get in touch

Synbias Pharma AG

Adress
Pestalozzistrasse 2,
8200 Schaffhausen,
Switzerland
logo
Synbias-Gemini Group © 2015 - 2024. All rights Reserved
Cookies
We Use Essential Cookies Only

Our website uses only essential cookies that are necessary for its proper functioning. We do not use cookies for tracking or advertising purposes. For more details, please refer to our Privacy policy.